PDCD1 and non-small cell lung carcinoma: Vascular normalization coupled to PD-1 blockade via the PD-1×VEGF-A bispecific ivonescimab improved progression-free survival in first-line PD-L1-positive NSCLC, illustrating microenvironmental reprogramming as a lever for efficacy (164) (see Supplementary Table S6).